Recent News

• 06.11.2025 - Shareholder Meeting 2025 (Virtual)
• 06.11.2025 - Shareholder Meeting 2025 (Virtual)
• 05.20.2025 - ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
• 05.20.2025 - ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
• 05.12.2025 - ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
• 05.12.2025 - ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
• 05.07.2025 - ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
• 05.07.2025 - ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
• 04.29.2025 - ZyVersa’s inflammasome inhibitor shown to address key hallmarks of Parkinson’s disease pathology – inflammation and protein misfolding.
• 04.29.2025 - ZyVersa’s inflammasome inhibitor shown to address key hallmarks of Parkinson’s disease pathology – inflammation and protein misfolding.

Recent Filings

• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.17.2025 - DEF 14A Other definitive proxy statements
• 04.17.2025 - ARS Annual Report to Security Holders
• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.09.2025 - EFFECT Notice of Effectiveness